// App-Quantinova.ai

915 : Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial

Researchers

Presenter

  • Dong-Wook Kim

Principal Investigators

  • Javier Pinilla-Ibarz

  • Philipp le Coutre

  • Ronald Paquette

  • Hagop M. Kantarjian

Medical Centers

  • Urologische Klinik Universitatsmedizin Mannheim, Mannheim, Germany

  • Ematologia, Ospedale S. Eugenio, Universita Tor Vergata, Rome, Italy

  • Institute of Pathology, Charite Universitatsmedizin Berlin, Berlin, Germany

  • Department of Haematology, SA Pathology and Royal Adelaide Hospital, Adelaide, Australia

  • Department of Hematology, Singapore General Hospital, Cancer and Stem Cell Biology Program, Duke-NUS Graduate Medical School, Singapore

  • Centre Hospitalier Lyon-Sud, Pierre-Benite, France

  • Department of Obstetrics and Gynecology, Universitatsklinikum Halle, Halle, Germany

  • H. Lee Moffitt Cancer Center & Imperial College, Department of Haematology, Hammersmith Hospital, London, United Kingdom

  • Division of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, South Korea,

  • Service des Maladies du Sang, Hopital Saint-Louis, Paris, France

  • Unita di Ricerca Clinica - Ematologia, Azienda Ospedaliera San Gerardo/University of Milano Bicocca, Monza, Italy

  • Centre for Haematology, Imperial Collegel, London, United Kingdom

  • CHU Poitiers, Poitiers, France

Locations

  • Republic of South Korea

  • Italy

  • Singapore

  • Germany

  • United Kingdom

  • Australia

  • France

Companies

  • ARIAD Pharmaceutical

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Acute lymphoblastic leukemia

  • Chronic Myelogenous Leukemia

  • Thrombocytopenia

  • Pancreatitis

  • Neutropenia

Biomarkers

  • Breakpoint Cluster Region

  • Cluster of Differentiation 206

Drug/Treatment

  • Nilotinib

  • Ponatinib

  • dasatinib

  • Imatinib

  • IkT001

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • open label

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved